Drug Trial Radar · NCT04498741
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Oct 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Jul 8, 2020
Primary completion
May 27, 2021
Study completion Jun 1, 2021
Sponsor
- Lead sponsor
- Enanta Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Pharmaceutical Research Associates
- First posted
- Aug 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of tacrolimus, dabigatran, rosuvastatin and midazolam on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Conditions
- RSV Infection
Interventions
EDP-938Drug
Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
EDP-938Drug
Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
EDP-938Drug
Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
TacrolimusDrug
Subjects will receive tacrolimus once daily on Day 1 and Day 24
DabigatranDrug
Subjects will receive dabigatran once daily on Day 1 and Day 13
RosuvastatinDrug
Subjects will receive rosuvastatin once daily on Day 1 and Day 13
EDP-938Drug
Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
MidazolamDrug
Subjects will receive midazolam once daily on Day 1 and Day 16
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of tacrolimus with and without coadministration with EDP-938Time frame: up to 29 days
- AUC of tacrolimus with and without coadministration with EDP-938Time frame: up to 29 days
- Cmax of dabigatran with and without coadministration with EDP-938Time frame: up to 17 days
- AUC of dabigatran with and without coadministration with EDP-938Time frame: up to 17 days
- Cmax of rosuvastatin with and without coadministration with EDP-938Time frame: up to 17 days
- AUC of rosuvastatin with and without coadministration with EDP-938Time frame: up to 17 days
- Cmax of midazolam with and without coadministration with EDP-938Time frame: up to 17 days
- AUC of midazolam with and without coadministration with EDP-938Time frame: up to 17 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaceutical Research Associates, Inc.,
Lenexa, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.